TY - JOUR
T1 - Closure of a patent foramen ovale is associated with a decrease in prevalence of migraine
T2 - A prospective observational study
AU - Luermans, Justin G.L.M.
AU - Post, Martijn C.
AU - Temmerman, Frederik
AU - Thijs, Vincent
AU - Schonewille, Wouter J.
AU - Plokker, H. W.Thijs
AU - Suttorp, Maarten J.
AU - Budts, Werner I.H.L.
PY - 2008/10/1
Y1 - 2008/10/1
N2 - Background - A causal relationship between migraine and a right-to-left shunt, due to a patent foramen ovale (PFO), has been suggested. In mainly retrospective studies, percutaneous closure of a PFO has been associated with a decrease in the prevalence of migraine. Objective - In this prospective observational study we evaluated whether percutaneous closure of a PFO is associated with a decrease in the prevalence of migraine. Methods - Between November 2003 and August 2005, we included 92 patients (age≥ 16 years) who underwent a percutaneous closure of a symptomatic PFO, which was considered to be related to a paradoxical embolism.They received a headache questionnaire before and six months after closure. Two neurologists diagnosed migraine, according to the International Headache Criteria. Results - Eighty-nine of 92 patients (97%, mean age 51.6 ± 12.3 years, 63 men) completed the questionnaire immediately before PFO closure.The overall prevalence of migraine was 27.0%, for migraine without aura (MA-) 15.7%, and for migraine with aura (MA+) 11.2%.After more than six months of follow-up 84 of 89 patients (94%, mean age 52.1 ± 12.0 years, 60 men) returned the questionnaire. The overall prevalence of migraine in this group decreased from 28.6% to 10.7% (P = 0.001), for MA- from 16.7% to 8.3% (P = 0.07), and for MA+ from 11.9% to 2.4% (P = 0.02). Conclusions - Percutaneous PFO closure is related to a decrease in the prevalence of migraine in this prospective observational study. However, randomized placebo controlled trials have to confirm these findings.
AB - Background - A causal relationship between migraine and a right-to-left shunt, due to a patent foramen ovale (PFO), has been suggested. In mainly retrospective studies, percutaneous closure of a PFO has been associated with a decrease in the prevalence of migraine. Objective - In this prospective observational study we evaluated whether percutaneous closure of a PFO is associated with a decrease in the prevalence of migraine. Methods - Between November 2003 and August 2005, we included 92 patients (age≥ 16 years) who underwent a percutaneous closure of a symptomatic PFO, which was considered to be related to a paradoxical embolism.They received a headache questionnaire before and six months after closure. Two neurologists diagnosed migraine, according to the International Headache Criteria. Results - Eighty-nine of 92 patients (97%, mean age 51.6 ± 12.3 years, 63 men) completed the questionnaire immediately before PFO closure.The overall prevalence of migraine was 27.0%, for migraine without aura (MA-) 15.7%, and for migraine with aura (MA+) 11.2%.After more than six months of follow-up 84 of 89 patients (94%, mean age 52.1 ± 12.0 years, 60 men) returned the questionnaire. The overall prevalence of migraine in this group decreased from 28.6% to 10.7% (P = 0.001), for MA- from 16.7% to 8.3% (P = 0.07), and for MA+ from 11.9% to 2.4% (P = 0.02). Conclusions - Percutaneous PFO closure is related to a decrease in the prevalence of migraine in this prospective observational study. However, randomized placebo controlled trials have to confirm these findings.
KW - Migraine
KW - Patent foramen ovale
KW - Transcatheter closure
UR - http://www.scopus.com/inward/record.url?scp=56049094117&partnerID=8YFLogxK
U2 - 10.2143/AC.63.5.2033223
DO - 10.2143/AC.63.5.2033223
M3 - Article
C2 - 19013999
AN - SCOPUS:56049094117
SN - 0001-5385
VL - 63
SP - 571
EP - 577
JO - Acta Cardiologica
JF - Acta Cardiologica
IS - 5
ER -